Evogene Ltd.
EVGN
$0.97
-$0.0255-2.56%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -84.66% | 475.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -84.66% | 475.99% | |||
| Cost of Revenue | -22.11% | 10.85% | |||
| Gross Profit | -94.47% | 1,587.05% | |||
| SG&A Expenses | -4.76% | -12.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.22% | -7.07% | |||
| Operating Income | -82.36% | 47.06% | |||
| Income Before Tax | -90.03% | 50.20% | |||
| Income Tax Expenses | 20.00% | -123.81% | |||
| Earnings from Continuing Operations | -90.18% | 50.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 684.13% | -116.69% | |||
| Net Income | -65.69% | 43.27% | |||
| EBIT | -82.36% | 47.06% | |||
| EBITDA | -97.76% | 51.45% | |||
| EPS Basic | -60.25% | 51.71% | |||
| Normalized Basic EPS | -41.67% | 47.17% | |||
| EPS Diluted | -60.25% | 51.71% | |||
| Normalized Diluted EPS | -41.67% | 47.17% | |||
| Average Basic Shares Outstanding | 3.40% | 17.48% | |||
| Average Diluted Shares Outstanding | 3.40% | 17.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||